Investigational Ygalo Shows Promise for Relapsed or Refractory Multiple Myeloma, Interim Data Show
Ygalo (melflufen), a novel compound…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreYgalo (melflufen), a novel compound…
New data from a Phase 1 clinical trial show…
OncoTracker has acquired worldwide rights to a diagnostic test…
The European Medicines Agency‘s (EMA) Committee for Medicinal…
The U.S. Food and Drug Administration is delaying its…
An application has been submitted seeking U.S. approval of…